NIKKEI 225
39,236.17 +166.49 (+0.43%) HANG SENG
19,636.22 +82.61 (+0.42%) CRUDE OIL
79.72 -0.08 (-0.10%) GOLD FUTURES
2,431.90 -6.60 (-0.27%) DOW
39,806.77 -196.82 (-0.49%) Bitcoin GBP
56,054.36 +3,771.97 (+7.21%)
Traws Pharma, Inc. (TRAW)
After hours:
- GlobeNewswire
Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
Completed acquisition of Trawsfynydd and concurrent $14 million Capital Raise Excellent pipeline progress, led by candidates for COVID 19, influenza, and oncology programs Poised to initiate Phase 2 studies in H2 2024 for our influenza candidate and ritonavir-free COVID 19 protease inhibitor NEWTOWN, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases and ca
- GlobeNewswire
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
Investigational travatrelvir demonstrated preclinical activity against multiple SARS-CoV-2 variants Orally administered novel protease inhibitor does not require ritonavir co-administration First-in-Human study to evaluate safety, tolerability and pharmacokinetics in healthy volunteers Topline Phase 1 data and Phase 2 initiation expected in H2 2024 NEWTOWN, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing
- Simply Wall St.
Traws Pharma Full Year 2023 Earnings: Beats Expectations
Traws Pharma ( NASDAQ:TRAW ) Full Year 2023 Results Key Financial Results Net loss: US$18.9m (flat on FY 2022). US$0.90...
